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Abstract
Background and aims: Clinical management of inflammatory bowel diseases (IBD), new
treatment modalities and the potential impact of personalised medicine remain topics of
intense interest as our understanding of the pathophysiology of IBD expands.
Methods: Potential future strategies for IBD management are discussed, based on recent
preclinical and clinical research.
Results: A top-down approach to medical therapy is increasingly being adopted for patients with
risk factors for severe inflammation or an unfavourable disease course in an attempt to halt the
inflammatory process as early as possible, prevent complications and induce mucosal healing. In
the future, biological therapies for IBD are likely to be used more selectively based on
personalised benefit/risk assessment, determined through reliable biomarkers and tissue
signatures, and will probably be optimised throughout the course of treatment. Biologics with
different mechanisms of action will be available; when one drug fails, patients will be able to
switch to another and even combination biologics may become a reality. The role of
biotherapeutic products that are similar to currently licensed biologics in terms of quality,
safety and efficacy – i.e. biosimilars – is at an early stage and requires further experience. Other
therapeutic strategies may involve manipulation of the microbiome using antibiotics, probiotics,sentations made during the ‘Leading change in IBD’meeting held in Madrid on 18–19 January 2013 and
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727Future directions in IBD managementprebiotics, diet and combinations of all these approaches. Faecal microbiota transplantation is
also a potential option in IBD although controlled data are lacking.
Conclusions: The future of classifying, prognosticating and managing IBD involves an
outcomes-based approach to identify biomarkers reflecting various biological processes that
can be matched with clinically important endpoints.
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The conventional approach to managing active inflammatory
bowel diseases (IBD) has been based on progressive intensifica-
tion of therapy as disease worsens.1,2 This strategy is focused on
inducing andmaintaining clinical remission, allowing withdraw-
al of corticosteroids and preventing post-operative recurrence
of disease. The direction of IBD management has recently been
altered by advances in our understanding of the pathophysiol-
ogy of Crohn's disease (CD) and ulcerative colitis (UC), increased
ability to monitor underlying inflammatory processes and the
advent of biological treatments that directly target proinflam-
matory mediators. This paper explores the future of IBD
management in the clinic, new directions and modalities for
treatment and the potential impact of personalised medicine
on IBD.2. The future of the clinical management of IBD
CD and UC are progressive inflammatory diseases that
usually lead to irreversible damage to the gastrointestinal
tract requiring surgical resections of the intestine. There is
growing consensus that the ultimate goal of IBD management
is to attain complete disease control and stop disease
progression, altering the natural course of IBD. Based on
this goal, key therapeutic outcomes have moved beyond
clinical symptom control to include steroid-free remission,
biological remission (that is, normalisation of inflammatory
biomarkers such as C-reactive protein) and mucosal healing
(also known as endoscopic remission).3 Mucosal healing
usually leads to significantly better clinical outcomes,
reduced resource utilisation and restored quality of life.4–9Several studies have suggested that more aggressive
therapy at an earlier stage of disease may improve clinical
outcomes and possibly increase the likelihood of achieving
mucosal healing. For example, CD patients randomised to early
treatment with infliximab and azathioprine in the Step-Up,
Top-Down Study had an increased likelihood of achieving
clinical remission, steroid-free remission and mucosal healing
compared with patients treated with corticosteroids, followed
in sequence (if necessary) by azathioprine and infliximab.10 In
addition, post-hoc analyses of randomised controlled trials
have shown that patients who received biological therapy at an
earlier stage of disease achieved better treatment outcomes
than those treated at a later stage of disease.11,12 Combination
therapy with infliximab and azathioprine has been shown to be
a more efficacious first-line CD treatment than either agent as
monotherapy13; however, the risk–benefit ratio of combina-
tion therapy must be carefully weighed up.14
Rather than applying a universal treatment strategy to all
patients, it has been suggested that severity of disease at
presentation can be used to guide therapy in newly-diagnosed
CD.3,15,16 A top-down approach to medical therapy is increas-
ingly being adopted for patients with risk factors for severe
inflammation or an unfavourable disease course in order to halt
the inflammatory processes as early as possible. Patients with
mild-to-moderate inflammation and fewer risk factors should
be considered for accelerated step-up treatment. Patients with
stricturing and/or penetrating disease, fistulae or abscesses at
first presentation may need early surgery, preferentially
followed by colonoscopy at 6–12 months to detect any disease
recurrence and allow timely intervention with medication,
preventing further bowel damage.3 Several small studies have
suggested that prophylactic use of anti-tumour necrosis factor
(TNF) agents prevents post-operative recurrence to a greater
degree than antibiotics or immunomodulators.17,18
728 G.R. D'Haens et al.2.1. Advances in biological strategies
There are a number of remaining questions with regard to
the optimal use of anti-TNF therapy (Box 1). Of particular
importance is the use of therapeutic drug monitoring to
guide clinical decision making.19 In patients treated with
anti-TNF monoclonal antibodies, low serum trough drug
concentrations may lead to lack or loss of response20,21 and
can be a consequence of the formation of anti-drug
antibodies, which may also cause acute or delayed infusion
reactions.22,23 Therapeutic drug monitoring makes it possi-
ble to determine if modifications to the drug regimen are
required to increase concentrations (e.g. increasing the dose
or dosing more frequently) or whether the patient should be
switched to another treatment.24 However, therapeutic
drug monitoring in clinical practice is limited at present, as
prospective data on optimal strategies are still missing and it
can take between two and three weeks to get a laboratory
result.25 The development of new assays, such as a dried
blood spot test, should allow more timely modifications to
anti-TNF treatment.26
Other means of blocking TNF are also in the pipeline,
including anti-TNF vaccination (in phase II trials in CD), TNF
gene silencing with small interfering RNA (in preclinical
development) and TNF-neutralising nanobodies (in preclin-
ical development). Furthermore, biological therapy for IBD
is expanding beyond anti-TNF therapies to include blockade
of other inflammatory mediators and inflammatory process-
es (Table 1).2.2. Adding patient-tailored medicine to algorithms
Decision making in IBD care is generally algorithm based;
however, it is likely that patient-tailored approaches may
change the way we manage individual patients. Given theBox 1 How do we further optimise anti-TNF therapy in IBD?
• Should anti-TNFs be used earlier in the course of
disease?
• Should anti-TNFs be used in a broader range of
patients?
• Which anti-TNF should be used in a particular
patient?
• What is the optimal duration of anti-TNF therapy?
• When do we stop treating a patient with
anti-TNFs?
• What are the mechanisms for primary non-
response to anti-TNFs and can this be avoided?
• How do we proactively prevent loss of response to
anti-TNFs?
• When should we consider switching anti-TNFs?
• Which patients are at risk for immunogenicity to
anti-TNFs and how do we address this?
• Can we reduce the risk of infections and lympho-
mas with anti-TNF therapy?
IBD, inflammatory bowel diseases; TNF, tumour
necrosis factor.importance of mucosal healing, endoscopy or surrogate
markers for mucosal ulcers should be the main decision tool
in the treatment of IBD. Other tools for patient-tailored
decision making include measures of clinical improve-
ment,27–30 change in inflammatory markers (such as
C-reactive protein and faecal calprotectin),31–35 drug toler-
ance and drug monitoring. In the future, it is likely that a
patient's mucosal gene signature will help predict response
to a particular drug.36–39 These molecular assays will be used
to determine which specific therapy should be used for the
individual's condition, leading to personalised or stratified
medicine.40
2.3. The future of clinical trials in IBD
Clinical trials in IBD need to adapt to evolving management
strategies and therapeutic goals. Objective primary end-
points measured with standardised instruments should
become the norm, particularly mucosal healing. This will
have the benefit of limiting placebo response and reducing
patient accrual requirements.41,42 Trials will need to stratify
for patient characteristics, at both clinical and biomarker
levels, which will have the advantage of increasing study
power, thereby reducing the number of patients required to
show an effect. While individual drugs will still require
robust evaluation in randomised controlled trials, therapeu-
tic strategies will also need to be evaluated. This has al-
ready been initiated in patients with CD in the REACT-1 and
REACT-2 studies, which compared usual care to that of a
treatment algorithm (REACT-1) or a step-care algorithm (that
specifies treatment escalation solely on the basis of symp-
toms) with an accelerated care algorithm (that features the
early use of combined antimetabolite/adalimumab therapy
with treatment intensification based on ileocolonoscopic
findings; REACT-2). The results of these studies should provide
much-needed insight into approaches to personalised
medicine in CD.
3. Biosimilars: new hope or much ado about
nothing?
While there is always hope for new drugs with novel mech-
anisms of action in the treatment of IBD, more practical
and cost-effective methods of using our current knowledge
also need to be explored. For many years, generic small-
molecule drugs have been introduced once patents expire on
the originator product, with cost-savings to patients and
healthcare systems. As patents and exclusivities begin to
expire on biological drugs, follow-on products to innovator
biologicals can also be marketed by different manufac-
turers. These have been termed “biosimilars” and can be
defined as a “biotherapeutic product which is similar in
terms of quality, safety and efficacy to an already licensed
reference biotherapeutic product”, with similarity defined
as the “absence of a relevant difference in the parameter of
interest”.43
However, while a generic medicine is an exact copy of a
small-molecule drug and is identical to the original product
in terms of its structural and therapeutic identity, the same
cannot be said for biosimilars. Biological drugs are made in
living cell lines and are intrinsically complex proteins. They
Table 1 Novel therapeutic approaches to the treatment of
inflammatory bowel disease. Mechanisms of action are
shown in bold with examples of agents in phase II and phase
III development documented.
Anti-cytokines Selective
anti-migration agents
Cellular therapies
Crohn's disease
Anti-IL-12/-23
mAb
• Ustekinumab;
phase III
JAK inhibitor
• Tofacitinib;
phase III
Anti-IL-23
mAb
• MEDI-2070;
phase II
• AMG 139;
phase I
Anti-IL-6 mAb
• PF-04236921;
phase II
Anti-IL-13
mAb
• QAX576;
phase II
TLR-9 agonist
• BL-7040;
phase II
Anti-α4β7 mAb
• Vedolizumab;
phase III
• AMG-181; phase II
CCR9 antagonist
• GSK-1605786;
phase III
• CCX282-B; phase
II
Anti-CXCL-10 mAb
• BMS-936557;
phase II
Anti-MAdCAM mAb
• PF-00547659;
phase II
Anti-NKG2D mAb
• NN8555; phase II
Anti-β7 mAb
• rhuMAb Beta7;
phase II
Human stem
cells
• Cx601; phase
III
• Prochymal;
phase III
• PDA001; phase
II
Bone marrow
transplant
Treg cells
Ulcerative colitis
JAK inhibitor
• Tofacitinib;
phase III
Anti-α4β7 mAb
• AMG-181; phase II
Anti-MAdCAM mAb
(continued on next page)
Table 1 (continued)
Anti-cytokines Selective
anti-migration agents
Cellular therapies
TLR-9 agonist
• BL-7040;
phase II
• PF-00547659;
phase II
CCR9 antagonist
• GSK-1605786;
phase II
Anti-CXCL-10 mAb
• BMS-936557;
phase II
Anti-β7 mAb
• rhuMAb Beta7;
phase II
Anti-eotaxin-1 mAb
• Bertilimumab;
phase II
729Future directions in IBD managementare sensitive to changes in the manufacturing process,
including type of expression system, growth conditions,
purification process, formulation and storage conditions
(Fig. 1).44,45 Differences in impurities and/or breakdown
products can affect immunogenicity. Originator products
may also have undergone manufacturing changes after their
approval and may no longer be identical to the medicine that
was originally authorised.46–48
Creating biosimilar monoclonal antibodies is notably more
complicated than biosimilar small proteins because of their
large and complex structure; therefore, specific guidelines on
biosimilar monoclonal antibodies have been recently issued by
the European Medicines Agency (EMA).44,49 The EMA states that
there can be no clinically meaningful differences between the
biosimilar and the reference product in terms of quality, safety
or efficacy49 while the US Food and Drug Administration states
that there can be no clinically meaningful differences in
“safety, purity and potency”.50
The goal of biosimilar development is to establish
biosimilarity, not to re-establish clinical efficacy and safe-
ty.44,49,51 In vitro characterisation studies are required, where
the biosimilar and the reference product are compared in terms
of binding and function. In vivo testing may be required if there
are concerns identified in in vitro studies. Clinical evaluations
are required to evaluate pharmacokinetics, pharmacodynam-
ics, efficacy and safety. In addition, pharmacovigilance
plans will be required to evaluate long-term safety,
730 G.R. D'Haens et al.particularly immunogenicity.52,53 Immunogenicity is a
significant concern, as its impact on longer-term clinical
benefit and risk is uncertain.53 It is unclear at present what
the acceptable margin of difference in immunogenicity
between a biosimilar and the reference product is.
In September 2013, the first infliximab biosimilar was
approved by the European Commission. This biosimilar had
shown similar efficacy and safety to the originator medicine
in a phase III trial in rheumatoid arthritis,54 with EMA
Committee for Medicinal Products for Human Use (CHMP)
extrapolating its approved indications to other rheumatolo-
gy, dermatology and IBD conditions. The availability of such
biosimilars provides important opportunities to reduce the
cost of treatment with monoclonal antibodies and make
regimens that include monoclonal antibodies available to
more patients. This is particularly relevant as the value of
early and aggressive treatment of IBD is increasingly
recognised. However, unlike with generic chemical drugs,
biosimilar development costs will still be comparatively
high; therefore, the cost savings may be relatively modest.
Furthermore, the uptake of biosimilars, in particular in the
extrapolated conditions, may not be as straightforward as
seen with generic chemical drugs. The interchangeability of
originator biologicals and biosimilars still remains an open
question and will probably depend on additional clinical and
post-marketing surveillance data. This may be further
influenced by the fact that both products may drift apart
due to potential manufacturing changes in either product.55
4. New strategies in the therapeutic
manipulation of the microbiome
Clinical evidence has shown that enteric bacteria, viruses or
fungi can induce chronic, immune-mediated intestinal
inflammation in genetically susceptible hosts,56–60 depend-
ing on the relative balance of beneficial and detrimental
bacteria in an individual's digestive system. This abnormal
composition of gut bacteria is known as dysbiosis, and may
be influenced by genetic and environmental factors,
including diet.61 Comparison of clone libraries has revealed
statistically significant differences between the microbiotas of
CD and UC patients and those of non-IBD controls. Further-
more, a subset of IBD patients has depletion of key commensal
bacteria, notably members of the phyla Firmicutes and
Bacteroidetes.62 In addition, patient phenotype and geno-
type influence compositional changes in intestinal-associated
microbiota.63
Therapeutic manipulation of intestinal bacteria can target
selective alteration of beneficial species and/or detrimental
species. This may involve antibiotics, probiotics, prebiotics,
diet and combinations of all these approaches (for example,
probiotics and prebiotics, or antibiotics followed by
probiotics). A recent phase II trial found that the antibiotic
rifaximin in an extended intestinal release formulation
was able to effectively induce clinical remission of
moderately-active CD,64 although the lack of a dose–
response relationship and the higher than expected placebo
response means that these results need verification
in further studies. Some probiotics (for example, the VSL3
combination) have been shown to maintain antibiotic-
induced remission in relapsing pouchitis; however, nosustained remission was seen once the probiotic was
stopped.65–67 It is possible that beneficial commensal
strains of enteric bacteria may be better than probiotic
strains as these are more likely to grow and persist in
the intestine. In a proof-of-concept study, Sokol and
colleagues found that high mucosal concentrations of
Faecalibacterium prausnitzii at the time of resection were
associated with remission in patients with active CD
requiring ileocaecal resection.68 Furthermore, in mice,
murine and human indigenous Clostridium species were
able to induce colonic regulatory T (Treg) cells, known to
play a critical role in the maintenance of immune homeo-
stasis and attenuate experimental colitis.69,70 There has
also been a suggestion that diet can alter the composition of
gut bacteria with increased growth and function of
aggressive species associated with refined sugars, iron and
saturated fat; conversely, fibre and prebiotics have a
protective effect.71,72
Faecal microbiota transplantation or faecal bacteriotherapy,
whereby faecal bacteria are transplanted from a (healthy)
individual to a recipient, is also a potential option in IBD.
Multiple studies indicate that this is effective in patients with
recurrent Clostridium difficile infection.73–76 There have
been several case studies in IBD patients77; however, there
are a number of questions to be answered regarding
effectiveness, durability, preparation of patients, donor
sources and risks.
Current techniques can be improved to restore a healthy
microbiome. These potentially include selecting a customised
treatment approach based on analysis of an individual's
microbiota pattern and concentrating on protective commen-
sal species that have a good chance to colonise and func-
tion in the intestine. It is likely that combinations of
commensal protective species will be superior to a single
species. Refining bacteriotherapy and determining its
effectiveness in IBD will require long-term longitudinal
studies in carefully-characterised patients, as will deter-
mining if dietary approaches can alter composition and
function of enteric microbiota in a therapeutic/preventive
manner.5. Prognostic genomics in the management of
IBD
CD and UC are complex genetic diseases with a pathogenesis
characterised by exposure to environmental factors in a
genetically susceptible individual. The genetic architecture
of IBD is nearly complete, with the genome-wide association
approach successful in identifying multiple UC and CD
susceptibility loci. For example, in a recent landmark
meta-analysis of genome-wide studies followed by
immunochip validation phenotyping in 25,000 new cases,
163 loci were identified (71 new) that met genome-wide
significance thresholds.78 Most loci contributed to both
phenotypes, although several were specific to CD or UC.
However, at this stage it appears that genetic markers alone
are not sensitive or specific enough to have a role in
diagnosing or classifying IBD. Combining serological markers,
genetic variants, and markers of inflammation may give
better precision for discriminating between CD and UC.79
Figure 1 Manufacturing process of biological drugs and sources of variation between innovator biological and biosimilars.
Figure reproduced from Mellstedt et al.,45 with permission from Oxford University Press. (©) 2007.
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creating an evolution in how IBD may be classified in the
future. The model of IBD is transforming from one where
patients can be classified into discrete subtypes such as UC or
CD into one where there may be many subtypes of IBD
characterised by genetic markers, serum markers and other
immune or microbial biomarkers. Furthermore, it is becoming
increasingly evident that some of the genes implicated in IBD
overlap with those involved in other immune-related diseases,
with it likely that the microbiome or other environmental
factors determining the end organ that is ultimately affected.
Genetic analysis may also enable us to better prognosti-
cate for patients with IBD. Data from a genome-wide asso-
ciation study in medically-refractory UC patients showed
that a single nucleotide polymorphism (SNP)-based risk
scoring system was able to predict earlier progression to
colectomy.80 In a genetic study in CD patients, the presence
of several CD-associated polymorphisms was able to predict
the risk of internal penetrating disease.81 Combining genetic
markers with serologic markers is likely to give a better
prognostic yield and may provide a more objective means of
quantifying intestinal inflammation than those currently
used. For example, combining quantitative serologic im-
mune responses and NOD2 genotype in CD patients was able
to stratify the risk of disease complications.82 A NOD2polymorphism was significantly associated with ileal inflam-
mation in the pelvic pouch in UC patients, with further
precision added when combined with clinical and serologic
markers.83 Gene expression profiling may be more useful
than genomic analysis, as it may be more reflective of the
immediate clinical situation. In children with severe UC,
differential expression of several genes involved in inflamma-
tory pathways was associated with resistance to intravenous
corticosteroid therapy early in the course of treatment.84 In
similar fashion, a panel of differentially expressed genes
found in colonic biopsies of patients treated with infliximab
was able to separate responders from non-responders, with
95% sensitivity and 85% specificity.39 All of these approaches
require validation and independent replication before their
clinical utility can be considered.6. Summary and conclusions
In the future, biological therapies for both CD and UC will be
used selectively based on personalised benefit/risk assess-
ment and will be optimised throughout the course of
treatment. Choice of therapy will depend on individual
patient profiles, determined through reliable biomarkers
and tissue signatures. Drug monitoring will be part of
732 G.R. D'Haens et al.treatment optimisation. Treating to mucosal healing may
become the standard therapeutic goal and will be at the
centre of decision making. Biologics with different mecha-
nisms of action will be available; when one drug fails,
patients will be able to switch to another. Biosimilars have
the potential to make biological drugs more accessible to
patients with IBD; however, questions remain with regard to
their use and acceptance in this therapeutic field.
Altering the microbiome may be a more physiologic and
sustained approach to treating IBD than blocking effector
immune responses. Alternative physiological approaches to
promoting regulatory cell activity, restoring mucosal barrier
function and eliminating antigenic drive may be of increas-
ing importance in maintaining long-term remission. While
genetic testing for IBD disease classification, prognosis and
therapy selection sounds promising, use of this technique in
isolation may not result in clinically useful tools. The future
of classifying, prognosticating and managing IBD involves an
outcomes-based approach to identify biomarkers reflecting
various biological processes that can be matched with
clinically important endpoints.
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